About RongCan

RongCan（Shanghai）Biotech Co., Ltd is a sino-foreign joint venture founded by renowned professors, domestic experts and overseas doctoral researchers in June 2020. RongCan Biotech focuses on the development and industrialization of nucleic acid-based therapeutics, striving to become a whole-industry-chain company that covers from mRNA sequential design and synthesis, and LNP-based delivery systems to finished mRNA-based pharmaceutical products. As one of the few domestic R & D enterprises with special emphasis on innovative nucleic acid-based medicines, we have created proprietary RNA-based Therapeutic Platform (RTP) for development of mRNA-based vaccines and therapeutics to address unmet medical needs.

The company’s core team, one of the leading domestic R & D teams, has been extensively involved in the market-oriented research and development of nucleic acid delivery systems for more than ten years, resulting in a patent granted by USPTO. The cationic lipid described in the granted patent has been widely used by many famous scholars from within China and abroad to deliver mRNA and siRNA therapeutics for treatment of a wide variety of diseases. Our R & D team has created proprietary ionizable lipid-like compound libraries based on which multiple LNP-based mRNA delivery systems with independent intellectual property have been developed. The developed LNP carriers allow for an efficient and targeted delivery of mRNA therapeutics to the organs of interest, such as the lungs, livers and injured vascular wall. Additionally, cell and animal studies have demonstrated their excellent biocompatibility, suggesting that they are safe for potential clinical use.

Based on proprietary ionizable lipid-like compound libraries, the R&D teams create

LNP carriers that:

	Allow for an efficient and targeted delivery of mRNA therapeutics to the organs of interest, such as the lungs, livers and injured vascular wall;

	Demonstrate excellent biocompatibility, suggesting that they are safe for potential clinical use;

	Possess high transfection efficiency;

	Are applicable to various routes of medication.

Deep and Broad Expertise in mRNA- and LNP-based Technologies

Our team at RongCan consists of scientists and engineers from multidisciplinary fields including mRNA & protein biology, chemistry, formulation, and bioinformatics. The dedicated team is led by three Overseas Top Level Innovation Talents, who completed their joint Postdoctoral training at Massachusetts Institute of Technology and Harvard Medical School under the supervision of the founders of international nucleic acid medicine corporate giants, Moderna and Alnylam, and have extensive expertise in mRNA- and LNP-based Technologies.